Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Katherine S. Panageas, DrPH"'
Autor:
Brandon S. Imber, MD, MA, Ryka Sehgal, MD, Rachel Saganty, MD, Anne S. Reiner, MPH, A. Turan Ilica, MD, Emily Miao, PharmD, Bob T. Li, MD, Gregory J. Riely, MD, Helena A. Yu, MD, Katherine S. Panageas, DrPH, Robert J. Young, MD, Luke R.G. Pike, MD, DPhil, Nelson S. Moss, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100607- (2023)
Introduction: Patients with EGFR-mutant NSCLC have a high incidence of brain metastases. The EGFR-directed tyrosine kinase inhibitor osimertinib has intracranial activity, making the role of local central nervous system (CNS)-directed therapies, such
Externí odkaz:
https://doaj.org/article/eb50687c81bc4fa09768c4beb4a3d785
Autor:
Goldman DA; Debra A. Goldman, MS, and Katherine S. Panageas, DrPH, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY., Panageas KS; Debra A. Goldman, MS, and Katherine S. Panageas, DrPH, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Publikováno v:
JCO oncology practice [JCO Oncol Pract] 2021 Mar; Vol. 17 (3), pp. 158-159. Date of Electronic Publication: 2020 Dec 17.